Advil Liqui Gels — Class I drug recall D-0182-2023
Terminated recall by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon, reported 2023-02-01, distributed nationwide. Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled b
| Recall number | D-0182-2023 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Glaxosmithkline Consumer Healthcare Holdings DBA Haleon, Warren, NJ, United States |
| Recall initiated | 2022-12-06 |
| Classified | 2023-01-25 |
| Reported by FDA | 2023-02-01 |
| Terminated | 2024-02-26 |
| Distributed | Nationwide (US) |
| Quantity | 88,380 capsules |
| Reason classes | labeling |
| Lot numbers | R94065 |
| Expiration dates | 2024-02-29 |
Product
Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Distributed by: Pfizer, Madison, NJ 07940, UPC 3 0573 0169 49 3
Reason for recall
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0182-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.